This page is part of the CPG-on-EBMonFHIR Implementation Guide (1.0.2).

• Narrative Content
• XML
• JSON

: COVID19 Intensive Care Treatment Guideline - JSON Representation

Raw json | Download

{
  "resourceType" : "Composition",
  "id" : "COVID19IntensiveCareTreatmentGuideline",
  "meta" : {
    "profile" : [
      🔗 "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/guideline"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition COVID19IntensiveCareTreatmentGuideline</b></p><a name=\"COVID19IntensiveCareTreatmentGuideline\"> </a><a name=\"hcCOVID19IntensiveCareTreatmentGuideline\"> </a><a name=\"COVID19IntensiveCareTreatmentGuideline-en-US\"> </a><p><b>identifier</b>: Resource identifier/113-001</p><p><b>version</b>: 7.0</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system clinical-practice-guideline}, {https://data.cochrane.org/concepts/ e07eN1w1Rwswg4}\">Guidelines</span></p><p><b>category</b>: <span title=\"Codes:{https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-guideline-stage-classification S3}\">Evidence- and consensus-based guideline</span></p><p><b>date</b>: 2022-03-01</p><p><b>author</b>: <a href=\"Organization-AWMFOrganization.html\">Organization Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.</a></p><p><b>title</b>: Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline</p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Citation</td><td><a href=\"Citation-COVID19IntensiveCareTreatmentGuidelineCitation.html\">Citation COVID19_Intensive_Care_Treatment_Guideline</a></td></tr></table></div>"
  },
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "RI",
            "display" : "Resource identifier"
          }
        ]
      },
      "system" : "https://www.awmf.org/",
      "value" : "113-001"
    }
  ],
  "version" : "7.0",
  "status" : "final",
  "type" : {
    "coding" : [
      {
        "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
        "code" : "clinical-practice-guideline"
      },
      {
        "system" : "https://data.cochrane.org/concepts/",
        "code" : "e07eN1w1Rwswg4",
        "display" : "Guidelines"
      }
    ]
  },
  "category" : [
    {
      "coding" : [
        {
          "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-guideline-stage-classification",
          "code" : "S3",
          "display" : "Evidence- and consensus-based guideline"
        }
      ]
    }
  ],
  "date" : "2022-03-01",
  "author" : [
    {
      🔗 "reference" : "Organization/AWMFOrganization"
    }
  ],
  "title" : "Empfehlungen zur stationären Therapie von Patienten mit COVID-19 - Living Guideline",
  "relatesTo" : [
    {
      "type" : "citation",
      "resourceReference" : {
        🔗 "reference" : "Citation/COVID19IntensiveCareTreatmentGuidelineCitation"
      }
    }
  ],
  "section" : [
    {
      "title" : "Stationäre Therapie von COVID-19 Patienten",
      "code" : {
        "coding" : [
          {
            "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
            "code" : "guideline-recommendation",
            "display" : "Clinical practice guideline recommendation"
          }
        ]
      },
      "focus" : {
        🔗 "reference" : "PlanDefinition/COVID19VentilatedPatientsDexamethasoneApplicationPlan"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><strong>Systemische Steroide:</strong> Bei Patienten mit COVID-19- und Sauerstoff-Bedarf (Niedrigfluss-Sauerstoff-Insufflation, High-Flow Nasal Cannula, Nichtinvasive Beatmung/CPAP, invasive Beatmung) soll eine Therapie mit systemischen Kortikosteroiden erfolgen. Die Therapie sollte mit 6 mg Dexamethason p.o. oder i.v. über zehn Tage erfolgen.</div>"
      }
    },
    {
      "title" : "Stationäre Therapie von COVID-19 Patienten",
      "code" : {
        "coding" : [
          {
            "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/ceosys-code-system",
            "code" : "guideline-recommendation",
            "display" : "Clinical practice guideline recommendation"
          }
        ]
      },
      "focus" : {
        🔗 "reference" : "PlanDefinition/COVID19NonVentilatedPatientsDexamethasoneApplicationPlan"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><strong>Systemische Steroide:</strong> Bei Patienten mit moderater Erkrankung (hospitalisiert ohne Notwendigkeit von Niedrigfluss-Sauerstoff-Insufflation) soll keine Therapie mit systemischen Kortikosteroiden erfolgen.</div>"
      }
    }
  ]
}